Scholarlink

<p>This study aimed to identify spice essential oils (EOs) that could lower uric acid and alleviate hyperuricemia. The xanthine oxidase (XOD) inhibition of 24 spice EOs was evaluated in vitro, with citronella (CEO) and nutmeg (NEO) showing the highest inhibition rates of 82.75 ± 1.21% and 80.47 ± 4.43%, respectively. In a zebrafish model, CEO, NEO, and their combination significantly reduced uric acid levels (<i>p</i> &lt; 0.05), comparable to allopurinol. In a high uric acid mouse model, CEO and NEO also significantly inhibited XOD (<i>p</i> &lt; 0.001) and reduced uric acid levels (<i>p</i> &lt; 0.001). Network pharmacology predicted protein targets and pathways for their effects on hyperuricemia, and molecular docking suggested binding to the FAD region of XOD. Both essential oils exhibited potent XOD inhibition in vitro (IC<sub>50</sub> = 9.78&#xa0;µg/mL for CEO and 4.62&#xa0;µg/mL for NEO), and their major components—caryophyllene, α-pinene, myrcene, and longifolene—showed IC<sub>50</sub> values ranging from 0.39 to 1.06&#xa0;µg/mL. These findings suggest potential use of CEO and NEO in managing high uric acid levels.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Screening of spice essential oils and their active compounds with xanthine oxidase inhibitory activity: in vitro, in vivo and in silico approach

  • 期刊论文

  • 发表日期：

    2026年5月13日

查看全文
  • Hongpeng Yu,
  • Zizhen Li,
  • JinJin Yang,
  • Cansheng Ou,
  • Dong He,
  • Kegang Wu,
  • ZhengXiang Cui,
  • Xianghua Chai,
  • Xuejuan Duan

摘要

This study aimed to identify spice essential oils (EOs) that could lower uric acid and alleviate hyperuricemia. The xanthine oxidase (XOD) inhibition of 24 spice EOs was evaluated in vitro, with citronella (CEO) and nutmeg (NEO) showing the highest inhibition rates of 82.75 ± 1.21% and 80.47 ± 4.43%, respectively. In a zebrafish model, CEO, NEO, and their combination significantly reduced uric acid levels (p < 0.05), comparable to allopurinol. In a high uric acid mouse model, CEO and NEO also significantly inhibited XOD (p < 0.001) and reduced uric acid levels (p < 0.001). Network pharmacology predicted protein targets and pathways for their effects on hyperuricemia, and molecular docking suggested binding to the FAD region of XOD. Both essential oils exhibited potent XOD inhibition in vitro (IC50 = 9.78 µg/mL for CEO and 4.62 µg/mL for NEO), and their major components—caryophyllene, α-pinene, myrcene, and longifolene—showed IC50 values ranging from 0.39 to 1.06 µg/mL. These findings suggest potential use of CEO and NEO in managing high uric acid levels.